论文部分内容阅读
目的了解本院2012年1月-2016年6月耐碳青霉烯类肠杆菌科细菌(CRE)的标本分布及药敏情况,为临床治疗CRE提供有效指导意见。方法使用WHONET 5.6软件,回顾性收集2012年1月-2016年6月临床微生物实验室检出的CRE。结果 2012年1月-2016年6月共检出各类CRE 646株,CRE检出率为3.7%。主要的标本分布在痰液、尿液、腹腔液、胆汁等标本中。检出的前5位CRE分别是肺炎克雷伯菌、大肠埃希菌、奇异变形杆菌、阴沟肠杆菌、黏质沙雷菌;这5种细菌对第一代头孢菌素和第二代头孢菌素耐药,对阿米卡星较为敏感。结论 CRE的检出率从2012年-2016年上半年呈现出递增的趋势,CRE的耐药情况较为严重,应采取综合措施防止CRE的大规模流行。
Objective To understand the distribution of specimens and susceptibility to carbapenem-resistant Enterobacteriaceae (CRE) from January 2012 to June 2016 in our hospital and provide effective guidance for the clinical treatment of CRE. Methods The WHONET 5.6 software was used to retrospectively collect CRE from clinical microbiology laboratory from January 2012 to June 2016. Results From January 2012 to June 2016, all kinds of CRE 646 strains were detected. The detection rate of CRE was 3.7%. The main specimens distributed in sputum, urine, peritoneal fluid, bile and other specimens. The first five CREs detected were Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens; these five kinds of bacteria on the first-generation cephalosporins and second-generation cephalosporins Mycotoxins are more sensitive to amikacin. Conclusions The detection rate of CRE presents an increasing trend from the first half of 2012 to the first half of 2016. The drug resistance of CRE is more serious. Comprehensive measures should be taken to prevent the massive outbreak of CRE.